TL
BMY.RT

TrueWealth LLC’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

TrueWealth LLC’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$2K Hold
453
– – ﹤0.01% 658
2020
Q1 		$2K Buy
453
+57
+14% +$188 ﹤0.01% 670
2019
Q4 		$1K Buy
+396
New +$1.03K ﹤0.01% 726

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TrueWealth LLC's BMY.RT Position: Q2 2020 in Review

TrueWealth LLC held its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) position steady in Q2 2020 at 453 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

TrueWealth LLC first reported a position in BMY.RT in Q4 2019 and has held it in 3 quarters since. 583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • TrueWealth LLC held 453 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $2K as of Q2 2020.
  • TrueWealth LLC left its Bristol-Myers Squibb Company Contingent Value Rights share count unchanged in Q2 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of TrueWealth LLC's portfolio in Q2 2020, its #658 holding.
  • TrueWealth LLC first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 3 quarters since.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on TrueWealth LLC's 13F filing for Q2 2020, filed 15 Jul 2020.